Reports of known blacklegged tick bites appear to be a source of confusion for some clinicians. Only 20% or so of all patients with Lyme disease were aware of the bite that caused their infection. When a tick bite history is present, it is crucial to consider the bite in the broader clinical context. This activity will help physicians distinguish between symptomatic and asymptomatic blacklegged tick bites.
- Distinguish between asymptomatic and symptomatic blacklegged tick bites.
- Employ general management principles for asymptomatic and symptomatic blacklegged tick bites
Learners may receive credit for this course through either the Accreditation Council for Continuing Medical Education (ACCME) or the American Academy of Family Physicians (AAFP).
Invisible International is accredited by the Accreditation Council for Continuing Medical education (ACCME) to provide continuing medical education for physicians.
Invisible International designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ACCME Activity Release Date: 8/1/2023; Expiration 7/31/2024.
Additionally, this session, When a blacklegged tick bite is more than a bite, is approved for 0.25 enduring AAFP Prescribed credits.
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
The AAFP has reviewed One Health Medical Education for a Changing Climate, and deemed it acceptable for AAFP credit. Term of approval is from 01/02/2023 to 01/01/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure to Learners
CME content presented to learners is free of commercial bias. No product, service, or therapeutic option will be over‐represented when comparing competing products, services, and therapeutic options. When appropriate, generic names or trade names from several companies will be used. Unless otherwise noted, none of those who controlled content had any financial relationships with an ineligible company. When a planner or faculty member has disclosed a relevant relationship, that relationship has been mitigated by review of all planning and presentation content.
Planner: Elizabeth Lee-Lewandrowski, PhD, MPH, is a consultant for Quidel Ortho Diagnostic.
Evidence-based bibliography for further study
• https://www.cdc.gov/ticks/tickbornediseases/tick-bite-prophylaxis.html. Last accessed March 30, 2019.
• Steere AC, Sikand VK. The Presenting Manifestations of Lyme Disease and the Outcomes of Treatment. N Engl J Med 2003; 348:2472-2474.
• Steere AC, Dhar A, Hernandez J, Fischer PA, Sikand VK, Schoen RT, et al. Systemic Symptoms without Erythema Migrans as the Presenting Picture of Early Lyme Disease. Am J Med 2003;114:58-62.
• Smith RP, Schoen RT, Rahn DW, et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med. 2002 Mar 19;136(6):421-428.
• Tibbles CD, Edlow JA. Does this patient have erythema migrans? JAMA. 2007 Jun 20;297(23):2617-27.
• Magid D, Schwartz B, Craft J, Schwartz JS. Prevention of Lyme disease after tick bites. A cost-effectiveness analysis. N Engl J Med. 1992 Aug 20;327(8):534-41.
• Cameron D, Maloney E, Johnson L Evidence assessment and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther 2014 Sep; 12(9): 1103-1135.
• Piesman J, Hojgaard A. Protective value of prophylactic antibiotic treatment of tick bite for Lyme disease prevention: an animal model. Ticks Tick Borne Dis. 2012 Jun;3(3):193- 196.
• Wormser GP, Dattwyler RJ, Shapiro ED et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43(9):1089-1134.